For specificity studies, we included additional ANA positive SLE samples18 (n = 30; 100% ANA positive) which were analysed along with non-matched healthy control cohort from SSI (n = 20) and Odense University Hospital (OUH; n = 60), and non-matched disease-stated sera from OUH: Crohn’s disease19 (n = 10), RA (n = 30), antiphospholipid syndrome20 (APS, n = 30), hepatitis B21 (n = 4), and cancer22, 23 (n = 8). This evidence concerns the gene BTG3 and rheumatoid arthritis.